Mammary adenosis

Jump to navigation Jump to search

WikiDoc Resources for Mammary adenosis

Articles

Most recent articles on Mammary adenosis

Most cited articles on Mammary adenosis

Review articles on Mammary adenosis

Articles on Mammary adenosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mammary adenosis

Images of Mammary adenosis

Photos of Mammary adenosis

Podcasts & MP3s on Mammary adenosis

Videos on Mammary adenosis

Evidence Based Medicine

Cochrane Collaboration on Mammary adenosis

Bandolier on Mammary adenosis

TRIP on Mammary adenosis

Clinical Trials

Ongoing Trials on Mammary adenosis at Clinical Trials.gov

Trial results on Mammary adenosis

Clinical Trials on Mammary adenosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mammary adenosis

NICE Guidance on Mammary adenosis

NHS PRODIGY Guidance

FDA on Mammary adenosis

CDC on Mammary adenosis

Books

Books on Mammary adenosis

News

Mammary adenosis in the news

Be alerted to news on Mammary adenosis

News trends on Mammary adenosis

Commentary

Blogs on Mammary adenosis

Definitions

Definitions of Mammary adenosis

Patient Resources / Community

Patient resources on Mammary adenosis

Discussion groups on Mammary adenosis

Patient Handouts on Mammary adenosis

Directions to Hospitals Treating Mammary adenosis

Risk calculators and risk factors for Mammary adenosis

Healthcare Provider Resources

Symptoms of Mammary adenosis

Causes & Risk Factors for Mammary adenosis

Diagnostic studies for Mammary adenosis

Treatment of Mammary adenosis

Continuing Medical Education (CME)

CME Programs on Mammary adenosis

International

Mammary adenosis en Espanol

Mammary adenosis en Francais

Business

Mammary adenosis in the Marketplace

Patents on Mammary adenosis

Experimental / Informatics

List of terms related to Mammary adenosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Your Name

Synonyms and keywords: Synonym 1; Synonym 2; Synonym 3

Overview

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • On microscopic histopathological analysis, slit-like, smaller acini that are in lobular arrangements and fibrosis which surround the acini are characteristic findings of mammary adenosis.
  • In mammary adenosis enlarged acini become slightly distorted by surrounded stromal fibrosis. However, adenosis and sclerosing adenosis retain the lobular architecture, but it becomes exaggerated and distorted. Fibrosis can mimic a desmoplastic reaction.

Immunohistochemistry

  • Fibrosis is pink on H&E stain.

Associated Conditions

  • Mammary adenosis can be seen as a component of other proliferative lesions, such as:
  • Intraductal and/or sclerosing papilloma and complex sclerosing lesion, and can be present within fibroadenomas
  • Invasive and in situ cancers

Causes

  • [Disease name] may be caused by either [cause1], [cause2], or [cause3].
  • [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
  • There are no established causes for [disease name].

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

Mammary adenosis accounts for approximately 12% of breast biopsy specimens.

Age

  • Mammary adenosis is more commonly observed among patients aged 30-45 years.

Gender

  • Females are more commonly affected with mammary adenosis than males.

Race

  • There is no racial predilection for mammary adenosis.

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Symptoms

  • Symptoms of mammary adenosis may include the following:
  • Recurring pain that tends to be linked to the menstrual cycle.

Physical Examination

  • Physical examination may be remarkable for:
  • Multiple small, firm, tender lumps.
  • Mammary adenosis is not palpable in approximately 80% of the cases, however in some cases, it might cause skin retraction.
  • A lump may be felt and may be painful.

Laboratory Findings

  • There are no specific laboratory findings associated with mammary adenosis.

Imaging Findings

  • Mammography is the imaging modality of choice for mammary adenosis.
  • On mammograms, mammary adenosis is characterized by bilateral appearance of mammary adenosis, and often with diffuse and scattered microcalcifications, asymmetric density with microcalcifications, a solitary cluster of microcalcifications, or as a non-calcified mass.
  • On mammography, mammary adenosis may consist of architectural distortion, amorphous microcalcifications, or both. At times a mass lesion or asymmetrical density may be present. It can be therefore very difficult to mammographically distinguish from an infiltrating carcinoma.
  • When the rarer, unusual presentations occur, it is recommended to have the findings verified with a biopsy. When it presents as a mass it is referred to as either ‘nodular adenosis’ or ‘adenosis tumor’, but it is not a tumor and is not cancerous.


Other Diagnostic Studies

  • Mammary adenosis may also be diagnosed using biopsy.
  • Findings on biopsy includes a proliferation of elongated, obliterated, or distorted glands and tubules, in addition to hardening of surrounding collagen and stroma tissue. The condition is sometimes called fibrosing adenosis, or adenofibrosis, and tends to arise from problems with the terminal duct lobular unit. (TDLU)

On mammography, sclerosing adenosis may consist of architectural distortion, amorphous microcalcifications (which can be present in 40-55% of cases 5,6), or both. At times a mass lesion or asymmetrical density may be present. It can be therefore very difficult to mammographically distinguish from an infiltrating carcinoma. When these rarer, unusual presentations occur, it is best to have the findings verified with a biopsy. When it presents as a mass it is referred to as either ‘nodular adenosis’ or ‘adenosis tumor’, but it is not a tumor and is not cancerous.

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

References